CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
Virologic Monitoring of Poliovirus Type 2 after Oral Poliovirus Vaccine Type 2 Withdrawal in April 2016 — Worldwide, 2016–2017
-
May 26 2017
-
-
Source: MMWR Morbidity Mortal Weekly Rep. 66(20):538-542.
[PDF-144.90 KB]
Details:
-
Journal Article:Morbidity and Mortality Weekly Report (MMWR)
-
Personal Author:
-
Description:The Global Polio Eradication Initiative (GPEI) has made substantial progress since its launch in 1988; only 37 wild polioVirus type 1 (WPV1) cases were detected in 2016, the lowest annual count ever. Wild polioVirus type 3 has not been detected since November 2012, and wild polioVirus type 2 was officially declared eradicated in September 2015. This success is attributable to the wide use of live oral polioVirus vaccines (OPVs). Since 2001, numerous outbreaks were caused by the emergence of genetically divergent vaccine-derived polioViruses (VDPVs) whose genetic drift from the parental OPV strains indicates prolonged replication or circulation (1). In 2015, circulating VDPV type 2 (cVDPV2) outbreaks were detected in five countries Worldwide (Nigeria, Pakistan, Guinea, Burma, and South Sudan), and VDPV2 single events were reported in 22 countries. These events prompted the GPEI to withdraw the type 2 component (Sabin2) of trivalent OPV (tOPV) in a globally coordinated, synchronized manner in April 2016 (2,3), at which time all OPV-using countries switched to using bivalent OPV (bOPV), containing Sabin types 1 and 3. This report details for the first time the virologic tracking of elimination of a live vaccine that has been withdrawn from routine and mass immunization systems Worldwide (3). To secure elimination, further monitoring is warranted to detect any use of tOPV or monovalent OPV type 2 (mOPV2).
-
Subjects:
-
Source:
-
Series:
-
DOI:
-
ISSN:0149-2195 (print);1545-861X (digital);
-
Pubmed ID:28542124
-
Pubmed Central ID:PMC5657872
-
Document Type:
-
Pages in Document:5 pdf pages
-
Volume:66
-
Issue:20
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
